LONDON -- It's the holy grail of drug treatment for people with
liver-ravaging hepatitis C, but in Ontario, it's out of reach for all
but the wealthy.
Two new drugs have revolutionized care for those with hepatitis C.
Sovaldi was so ground-breaking its first-year sales outpaced every other
previous drug, including Viagra. Harvoni became only the seventh drug
ever to be designated by American regulators as a breakthrough therapy.
But though sales of Sovaldi and Harvoni shot through the roof
elsewhere, Ontarians with the disease and without private insurance are
playing a waiting game some won't survive.
Labels: access to treatment, Canada, cost of treatment, Ontario